The podcast provides peer-to-peer physician perspectives on targeted treatments in BTC, focusing on fibroblast growth factor receptor (FGFR) inhibitors. Topics include:FDA-approved targeted therapies for patients with cholangiocarcinoma Mechanism of action of FGFR inhibitors and review of the efficacy and safety data from pivotal trials Physician experience with managing common adverse events associated with FGFR inhibitors Considerations for the place of FGFR inhibitors in line of therapy, including discussion of new agents currently in development Featuring:Milind Javle, MD Hubert L. and Olive Stringer Professor, Gastrointestinal Medical OncologyAttending Physician, Program Lead, Biliary Cancer ProgramThe University of Texas MD Anderson Cancer CenterHouston, TXDirector, The Cholangiocarcinoma Foundation InternationalCholangiocarcinoma Research NetworkSalt Lake City, UTChair, NCI Task Force Hepatobiliary CancersAmit Mahipal, MBBS, MPH Director, Gastrointestinal Oncology, University Hospitals, Seidman Cancer CenterProfessor, Medicine, Case Western Reserve UniversityCleveland, OH

Ver todos los episodios